You might be surprised to find a pharmaceutical stock listed among the top CBD stocks to consider. But Jazz Pharmaceuticals (JAZZ -0.99%) has a direct and important connection with CBD. In 2018, the company's Epidiolex became the first CBD product made from the cannabis plant to win FDA approval.
Jazz actually didn't own Epidiolex at that time. It acquired GW Pharmaceuticals, which developed the CBD drug to treat epileptic seizures, for $6.7 billion in 2021. Epidiolex is not too far from generating annual sales of $1 billion or more, as some analysts projected after it was first approved in the U.S. Sales continue to pick up, as the drug is now approved in more than 35 countries outside the U.S.
Jazz also has other growth drivers in its lineup. Sleep disorder drug Xywav is gaining momentum. The company also launched its biliary tract cancer drug Ziihera in December 2024, and its newest product, Modeyso, used to treat diffuse midline glioma, was granted FDA approval in August 2025.
4. Trulieve Cannabis